The global expression vectors market is expected to witness lucrative growth over the forecast period owing to increasing demand of protein-based drugs. The other factors pre disposing to growth of expression vectors industry include high prevalence of infectious diseases, genetic disorders, and other lifestyle associated diseases. Advancement in protein expression techniques and introduction of advanced technologies in the field of genetics, molecular biology, and bioinformatics drive growth of market. Rising unmet medical needs due to the patent expiration of generic drugs is anticipated to boost market growth in order to develop novel drugs. Large scale production of human insulin and other protein based products that use expression vectors is anticipated to impact expression vectors market positively. Applications of expression vectors in the R&D of biomedical and biopharmaceutical products are expected to be a high impact rendering factor for the growth of this market over the forecast period. On the contrary, high expenditure involved in research employing expression vectors is a key restraint for market growth.
Expression vector market is segmented on the basis of types, applications, and end use. Bacterial, mammalian, yeast, and insect expression vectors are available in the global market. Yeast expression vectors market is further segmented into K. lactis, Pichia pastoris, and Saccharomyces cerevisiae expression vectors. Amongst the enlisted, bacterial vectors held the largest market share in 2014 owing to high transformation levels and simple transformation protocols. The mammalian expression vectors segment is expected to exhibit the fastest growth over the forecast period, owing to the ability of mammalian host systems to carry out assembly of recombinant proteins, folding, and complex post-translational modifications. On the basis of applications the expression vectors market can be classified into therapeutic, industrial, and research applications. Therapeutic application held the largest market share in 2014 owing to the higher incidence rate of oncology diseases which can be treated by use of expression vectors. Therapeutic application held the largest market share in 2014 and is anticipated to remain the fastest growing segment owing to the rise of therapeutic formulations based on recombinant technology for the treatment of metabolic disorders coupled with gene therapy for oncology diseases. Technological advancement in proteomics and novel product development for protein expression are expected to offer new opportunities for the segment growth. As per the end-use, expression vectors market can be segregated into pharmaceutical and biotechnology companies, contract research organizations (cros) & contract manufacturing organizations (cmos), and academic research institutes. Pharmaceutical and biotechnology companies held the largest share in 2014 in expression vectors market and are expected to continue its dominance in the coming seven years owing to the novel drug development and protein pharmaceuticals synthesis using recombinant DNA technology.
Geographically, expression vectors market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA. North America held substantial share in market in 2014. The major factors that attributed towards high share of the region include increasing scientific research and development of novel technologies in this region. Furthermore, increasing investment of the U.S. government and private companies in biology research indirectly accentuates growth of expression vectors market. However, Asia Pacific market is poised to be the fastest growing region during the forecast period. Growth in this region will be driven by factors such as competitive growth in the pharmaceutical and biotechnology sector, increasing penetration of companies in R&D activities in biotechnology perspective, and presence of key market players. Rising awareness and demand for biologics and improvement in health care infrastructure are the other factors that are anticipated to boost substantial growth of this region in expression vectors market in the coming seven years.
The prominent players in expression vectors market are Promega Corporation, Agilent Technologies, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Merck Millipore, QIAGEN, Clontech Laboratories, Inc., DNA2.0, New England Biolabs, Sigma-Aldrich Corporation, and GenScript USA Inc. The market strategies of the competitors include the collaboration with research organizations for the initiation of research related to bioinformatics and thereby maintain the market position. Market players are adopting and complying with new techniques and guidelines for experimentation in recombinant DNA technology to hold their position in expression vectors market. Companies are involved in development of genomics based methodologies using protein assay to for the development of new drugs acting on different targets for the treatment of chronic metabolic disorders.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.